Clinico-pathological information and mutation status
| Training set, all samples n=381 | Validation set, all samples n=80 | |
| n (%) | n (%) | |
| Gender | ||
| M | 209 (54.9) | 40 (50.0) |
| F | 172 (45.1) | 40 (50.0) |
| Age | ||
| Median | 68 yrs | 75 yrs |
| Localisation | ||
| Left | 202 (53.0) | 31 (38.8) |
| Right | 136 (35.7) | 30 (37.5) |
| Rectum | 37 (9.7) | 8 (10.0) |
| Unknown | 6 (1.6) | 11 (13.8) |
| T-stage | ||
| 1 | 4 (1.0) | 0 (0) |
| 2 | 53 (13.9) | 2 (2.5) |
| 3 | 296 (77.7) | 74 (92.5) |
| 4 | 27 (7.1) | 4 (5.0) |
| Unknown | 1 (0.3) | 0 (0) |
| N-status | ||
| N0 | 259 (68.0) | 50 (62.5) |
| N+ | 121 (31.8) | 30 (37.5) |
| Unknown | 1 (0.3) | 0 (0) |
| Distal metastasis in follow-up | ||
| No | 299 (78.5) | 68 (85.0) |
| Yes | 81 (21.3) | 12 (15.0) |
| Unknown | 1 (0.3) | 0 (0) |
| Stage | ||
| 1 | 51 (13.4) | 0 (0.0) |
| 2 | 205 (53.8) | 50 (62.5) |
| 3 | 116 (30.4) | 30 (37.5) |
| 4 | 8 (2.1) | 0 (0.0) |
| Unknown | 1 (0.3) | 0 (0) |
| Grade | ||
| Good | 101 (26.5) | 8 (10.0) |
| Moderate | 233 (61.2) | 52 (65.0) |
| Poor | 45 (11.8) | 16 (20.0) |
| Unknown | 2 (0.5) | 4 (5.0) |
| KRAS mutation | ||
| No | 266 (69.8) | 51 (63.7) |
| Yes | 115 (30.2) | 29 (36.3) |
| BRAF mutation | ||
| No | 339 (89.0) | 76 (95) |
| Yes | 42 (11.0) | 4 (5.0) |
| PI3KCA mutation | ||
| No | 337 (88.5) | 64 (80.0) |
| Yes | 44 (11.5) | 16 (20.0) |
| Any mutation | ||
| No | 206 (54.1) | 40 (50.0) |
| Yes | 175 (45.9) | 40 (50.0) |